In fact, combination therapies using recombinant TRAIL or agonistic anti-TRAIL receptor monoclonal antibodies together with other anti-cancer agents have shown improved efficacy for cancer treatment in vitro and in vivo through modulation of TRAIL-resistant mechanisms [7]. The gene discussed is TNFSF10; the disease is cancer.